Regeneron Pharmaceuticals, Inc. (REGN), Monday announced a collaboration with software company Truveta, Inc. and its collective of U.S. healthy systems, offering a strategic investment of $119.5 million in Truveta's Series C financing round and planning to launch the Truveta Genome Project.
The biotechnology company expects the project to expand DNA sequence-linked healthcare database, paving way for potential new genetic-based therapies and optimized healthcare services.
As per the terms of the collaboration, Regeneron Genetics Centers will have the exclusive rights to perform research-related sequencing on the collected samples and access to de-identified electronic health records provided by study participants.
Both the parties anticipate to utilize the data in the development of next-generation solutions for healthcare delivery and population health management, Regeneron added.
Moreover, California-based Illumina, Inc. (ILMN), a DNA sequencing and array-based technologies company, will also invest $20 million in Truveta's Series C financing round in support of the project.
In the pre-market hours, Regeneron's stock is trading at $695, down 0.27 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.